The lupus inhibitor in thromboembolic disease and intrauterine death in the absence of systemic lupus.
The lupus inhibitor in thromboembolic disease and intrauterine death in the absence of systemic lupus.
复制标题
在没有系统性狼疮的情况下，狼疮抑制剂可用于治疗血栓栓塞性疾病和宫内死亡。
DOI：
10.1111/j.0954-6820.1984.tb05010.x
复制
发表时间：
2009
影响因子：
--
通讯作者：
B. Gårdlund
中科院分区：
文献类型：
--
作者：
B. Gårdlund
本研究描述了使用一种改良的稀释凝血活酶试验来证明血浆中的狼疮凝血抑制剂。使用一阶段凝血抑制试验，其中测量供试血浆延长正常血浆凝血时间的能力。该方法易于操作，适合于日常使用。临床和实验室数据从5例患者的抑制剂，但没有系统性红斑狼疮。血栓栓塞的表现中观察到三名患者和产科并发症可能是由于胎盘血栓形成的两个。1例患者显示出血倾向，与凝血酶原缺乏症相关。许多病理凝血分析和其他实验室数据可能是由于体外狼疮抑制剂对带负电荷磷脂的亲和力。
This study describes the use of a modified dilute thromboplastin assay for demonstration of the lupus coagulation inhibitor in plasma. A one-stage clotting inhibition assay is used in which the ability of the test plasma to prolong the clotting time of normal plasma is measured. The method is easy to perform and suitable for routine use. Clinical and laboratory data from five patients with the inhibitor but without systemic lupus erythematosus are presented. Thromboembolic manifestations were observed in three patients and obstetric complications possibly due to placenta thrombosis in two. One patient showed a bleeding tendency, associated with prothrombin deficiency. A number of pathological coagulation analyses and other laboratory data may be due to affinity of the lupus inhibitor for negatively charged phospholipids in vitro.